BioCurex, Inc.(fka BOCX)

[bocxman]

reverse: just listened to the conference call related to YMI's japanese licensing deal. it is a great opportunity for the company but, as goldseeker said, very far away. daichi has to organize clinical trials in japan -- and that is not like a 510k for an assay. the company said they would receive milestones "in future years" based on the regulatory process. so...that explains the tepid response.

nonetheless looks like a very interesting little company with a lot of pipeline and decent relationships.

FYI -- the market cap of YMI is already at 170 million. Ours is only around $30 million. So, the market is already valuing YMI 6 times more than BOCX.